Stock Analysis
Viking Therapeutics, Inc. (VKTX) Stock Analysis
Viking Therapeutics, Inc. (VKTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Viking Therapeutics, Inc. (VKTX) currently has an AIQ Score of 41/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
VKTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $29.22 |
| AIQ Score | 41/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Buy |
| Market Cap | $3.45B |
| P/E Ratio (TTM) | -5.41 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.55 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.29 |
| Volume | 8.87M |
| 52-week range | $23.82-$43.10 |
| RSI 14 | 54.98 |
| 50-Day SMA | $29.33 |
| 200-Day SMA | $32.17 |
| Analyst Price Target | $79.67 |
| Next Earnings | Feb 10, 2027 |
VKTXViking Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum47
- Value—
- Quality33
- Risk resilience41
- Sentiment—
VKTX Stock Analysis Summary
Viking Therapeutics, Inc. (VKTX) currently has an AIQ Score of 41/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, VKTX has AIQ Score of 41/100 with Momentum base of 47/100 and fading Quality at 33/100. Wait for component alignment before adding exposure.
Healthcare · 5.95% stock move · VKTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is VKTX Bullish or Bearish Right Now?
VKTX currently has a bearish overall setup. Momentum is the strongest factor at 47/100, while Quality is weakest at 33/100. The current evidence suggests a bearish setup.
- - Analyst target implies +172.64% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (29 vs 12).
- - Momentum is weak at 47/100.
- - Risk Resilience is weak at 41/100.
- - Price is -9.17% below its 200-day SMA.
Current Consensus
VKTX's Technical Analysis Consensus is currently Buy, with 29 buy, 5 neutral, and 12 sell votes. VKTX's 14-day RSI is 54.98, which places the stock in a neutral momentum range. VKTX's beta is 1.29, indicating greater market sensitivity than the broad market.
What Changed in VKTX?
The largest recent change in VKTX is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the VKTX Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
VKTX Decision Framework
Public evidence layers, setup checks, and risk context for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. (VKTX) Stock Analysis
Viking Therapeutics, Inc. has an AIQ Score of 41/100 in a Bearish regime. Momentum is strongest at 47/100. Beta is 1.29, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | VKTX is in a Bearish AIQ regime with score 41/100. |
| Signal Conflict | The primary conflict is that momentum leads at 47/100 while quality lags at 33/100. |
| Factor Evidence | Momentum 47/100 · Quality 33/100 · Risk 41/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 47/100.
Momentum is 47/100 and RSI (14) is 55.0.
VKTX is in a Bearish regime at 41/100.
Risk factor is 41/100 with beta 1.29 and annual volatility 69.18%.
Current conflict: momentum leads at 47/100 while quality lags at 33/100.
VKTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
VKTX Fundamentals
VKTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
VKTX Technical Analysis
VKTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
VKTX Stock Catalysts
Track VKTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
VKTX Dividend Analysis
VKTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
VKTX Financial Data
VKTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
VKTX Risk Analysis
VKTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
VKTX Stock News
VKTX stock news, market tone, recent headlines, and catalyst context.
VKTX vs Biotechnology Peers
Current peer cohort: VKTX · VOR · VRDN · VSTM · XENE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| VKTX Current stock | 41/100 | — | 47/100 | 41/100 | -0.15 | 69.18% | Current |
| VOR Vor Biopharma Inc. | 66/100 | — | 72/100 | 46/100 | 1.15 | 93.53% | VKTX vs VOR |
| VRDN Viridian Therapeutics, Inc. | 58/100 | 37/100 | 91/100 | 46/100 | 0.43 | 71.98% | VKTX vs VRDN |
| VSTM Verastem, Inc. | 60/100 | 53/100 | 89/100 | 36/100 | 0.32 | 74.24% | VKTX vs VSTM |
| XENE Xenon Pharmaceuticals Inc. | 49/100 | — | 33/100 | 49/100 | 0.27 | 68.13% | VKTX vs XENE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for VKTX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching VKTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for VKTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
VKTX Stock FAQ
What is VKTX stock price today?
Viking Therapeutics, Inc.'s current stock price is $29.22. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is VKTX bullish or bearish right now?
VKTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is VKTX's market cap?
VKTX's market cap is $3.45B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is VKTX's current P/E ratio?
VKTX's current P/E ratio is -5.41 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is VKTX's RSI?
VKTX's 14-day RSI is 54.98 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is VKTX above its 50-day and 200-day moving averages?
VKTX is -0.36% from its 50-day SMA and -9.17% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is VKTX's next earnings date?
VKTX's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does VKTX pay a dividend?
VKTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.